Accueil>>PF-3450074

PF-3450074 (Synonyms: PF74)

Catalog No.GC39664

Le PF-3450074 (PF-74) est un inhibiteur spécifique de la protéine de capside (CA) du VIH-1 et affiche une inhibition À large spectre des isolats de VIH avec une puissance submicromolaire (EC50 = 8-640 nM).

Products are for research use only. Not for human use. We do not sell to patients.

PF-3450074 Chemical Structure

Cas No.: 1352879-65-2

Taille Prix Stock Qté
10mM (in 1mL DMSO)
50,00 $US
En stock
5mg
45,00 $US
En stock
10mg
81,00 $US
En stock
25mg
135,00 $US
En stock
50mg
225,00 $US
En stock
100mg
405,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PF-3450074 (PF-74) is a specifical inhibitor of HIV-1 capsid protein (CA) and displays a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC50=8-640 nM). PF-3450074 (PF-74) acts at an early stage of HIV-1 infection, inhibits viral replication by directly competing with the binding of CPSF6 and NUP153, and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle[1][2]. CPSF6: nuclear host factors cleavage and polyadenylation specific factor 6; NUP153: nucleoporin 153.

[1]. Xu JP, et al. Exploring Modifications of an HIV-1 Capsid Inhibitor: Design, Synthesis, and Mechanism of Action.J Drug Des Res. 2018;5(2). pii: 1070. Epub 2018 Aug 13. [2]. Shi J, et al. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization.J Virol. 2011 Jan;85(1):542-9.

Avis

Review for PF-3450074

Average Rating: 5 ★★★★★ (Based on Reviews and 3 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PF-3450074

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.